Showing results (221-230 of 235) with videos related to
Sort By:
Pageof 24
British Journal of Cancer|February 23, 2022
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS CAmelie de Gregorio, Wolfgang Janni, Thomas W P Friedl, et al.Clinical Breast Cancer|February 14, 2017
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast CancerAmelie Schramm, Fabienne Schochter, Thomas W P Friedl, et al.ESMO Open|March 22, 2025
Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assayW Janni, B Rack, T W P Friedl, et al.Clinical Breast Cancer|March 31, 2018
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR StudyNikola S Mutschler, Christoph Scholz, Thomas W P Friedl, et al.JCO Precision Oncology|February 17, 2022
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast CancerAmelie De Gregorio, Thomas W P Friedl, Jens Huober, et al.Journal of the National Cancer Institute|October 13, 2018
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and PrognosisElisabeth Trapp, Wolfgang Janni, Christian Schindlbeck, et al.Plos One|June 7, 2017
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trialB A S Jaeger, J Neugebauer, U Andergassen, et al.Oncology Research and Treatment|March 1, 2018
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-StudyFabienne Schochter, Brigitte Rack, Marie Tzschaschel, et al.JAMA Oncology|June 24, 2021
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical TrialThomas W P Friedl, Tanja Fehm, Volkmar Müller, et al.British Journal of Cancer|February 24, 2023
Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical valueAndré Franken, Annika Kraemer, Alicia Sicking, et al.Pageof 24